DNA Diagnostics Market Size, Share & Trends by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029
The global DNA diagnostics market is valued at an estimated USD 13.3 billion in 2024 and is projected to reach USD 21.2 billion by 2029, at a CAGR of 9.7% during the forecast period. Growth in the DNA diagnostics market is primarily driven by the increasing prevalence of chronic and infectious diseases, advancements in DNA diagnostics for personalized medicine, and increasing funding by healthcare-based companies. Personalized medicines help in making informed clinical decisions and alleviating the risk of adverse events. Thus, the increasing demand for personalized medicines is expected to offer significant growth opportunities for players operating in the DNA diagnostics market in the coming years.
“The reagents & kits segment is projected to witness highest growth rate in the DNA diagnostics market, by offering, during the forecast period”
Based on offering, the DNA diagnostics market is segmented into reagents & kits, instruments, and services & software. The frequent need for reagents & kits makes them a recurrent cost, and this recurrent purchasing requirement is one of the key contributors to market growth. The versatility of reagents & kits in accommodating diverse testing needs contributes to their extensive usage and market demand during the forecast period.
“The polymerase chain reaction (PCR) segment is projected to witness the highest growth rate in the DNA diagnostics market, by technology, during the forecast period.”
Based on technology, the DNA diagnostics market is segmented into polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies. PCR techniques have undergone extensive standardization, ensuring consistent and reliable results across different laboratories and platforms. Currently, PCR is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and quick turnaround time (4 to 6 hours). Small PCR instruments may need little or no maintenance. These factors are contributing to growth of this segment.
“The blood, serum, and plasma segment accounted for the largest market share of DNA diagnostics market, in 2023, by specimen”
Based on specimen, the DNA diagnostics market is segmented into blood, serum, and plasma, urine, and other specimens. Blood collection and processing procedures have undergone extensive standardization, ensuring consistent sample quality and reliability of test results. Standardized protocols and quality control measures enhance the accuracy and reproducibility of DNA diagnostic tests performed on blood samples. Which accounts for the largest market share of this segment in the DNA diagnostics market in 2023.
“The oncology testing segment is projected to witness the highest growth rate in the DNA diagnostics market, by application, during the forecast period”.
Based on application, the DNA diagnostics market is segmented into infectious disease diagnostics, oncology testing, prenatal, pre-implantation, myogenic disorders, and other applications. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. DNA diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.
“The diagnostic laboratories segment accounted for the largest share of the DNA diagnostics market in 2023, by end user”.
Based on end users, the DNA diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. Hospitals have increasingly outsourced diagnostic tests to diagnostic laboratories to reduce the costs and technical issues in managing laboratories. Many small and medium-sized private hospitals and clinics have adopted this trend, thereby driving growth in this segment.
“The Asia Pacific region is projected to witness highest growth rate in the DNA diagnostics market during the forecast period”
The global DNA diagnostics market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR in the DNA diagnostics market during the forecast period. Due to factors like government initiatives to raise awareness about early disease detection and routine health checkups, steadily rising healthcare costs, an increase in hospitals and clinical diagnostics laboratories in China and India, and strengthening research bases for diagnostic procedures across China, Japan, and India, the Asia Pacific market is anticipated to grow at the highest rate during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
Illumina, Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMйrieux (France), Hologic, Inc. (US), QIAGEN (Germany), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Revvity, Inc. (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), Grifols S.A. (Spain), Quidelortho Corporation (US), Amoy Diagnostics Co., Ltd (China), Molbio Diagnostics Pvt. Ltd. (India), Biocartis (Belgium), Exact Sciences Corporation (US), TBG Diagnostics Ltd (Australia), Genetic Signatures (Australia), and Vela Diagnostics (Singapore).
Research Coverage:
In this report, the DNA diagnostics market has been categorized based on technology (polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies), specimen (blood, serum, and plasma, urine, and other specimens), offering (reagents & kits, instruments, and services & software), end user (diagnostic laboratories, hospitals & clinics, application (infectious disease diagnostic, oncology testing, prenatal, pre-implantation, myogenic disorder, and other applications), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).
The report's coverage includes comprehensive details about the key factors impacting the growth of the DNA diagnostics market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, services offered, significant strategies, acquisitions, and partnerships, product launches, and other recent developments related to the DNA diagnostics market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging DNA diagnostics startups.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall DNA diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, trends, opportunities, and challenges.
The report provides insights on the following pointers:
“The reagents & kits segment is projected to witness highest growth rate in the DNA diagnostics market, by offering, during the forecast period”
Based on offering, the DNA diagnostics market is segmented into reagents & kits, instruments, and services & software. The frequent need for reagents & kits makes them a recurrent cost, and this recurrent purchasing requirement is one of the key contributors to market growth. The versatility of reagents & kits in accommodating diverse testing needs contributes to their extensive usage and market demand during the forecast period.
“The polymerase chain reaction (PCR) segment is projected to witness the highest growth rate in the DNA diagnostics market, by technology, during the forecast period.”
Based on technology, the DNA diagnostics market is segmented into polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies. PCR techniques have undergone extensive standardization, ensuring consistent and reliable results across different laboratories and platforms. Currently, PCR is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and quick turnaround time (4 to 6 hours). Small PCR instruments may need little or no maintenance. These factors are contributing to growth of this segment.
“The blood, serum, and plasma segment accounted for the largest market share of DNA diagnostics market, in 2023, by specimen”
Based on specimen, the DNA diagnostics market is segmented into blood, serum, and plasma, urine, and other specimens. Blood collection and processing procedures have undergone extensive standardization, ensuring consistent sample quality and reliability of test results. Standardized protocols and quality control measures enhance the accuracy and reproducibility of DNA diagnostic tests performed on blood samples. Which accounts for the largest market share of this segment in the DNA diagnostics market in 2023.
“The oncology testing segment is projected to witness the highest growth rate in the DNA diagnostics market, by application, during the forecast period”.
Based on application, the DNA diagnostics market is segmented into infectious disease diagnostics, oncology testing, prenatal, pre-implantation, myogenic disorders, and other applications. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. DNA diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.
“The diagnostic laboratories segment accounted for the largest share of the DNA diagnostics market in 2023, by end user”.
Based on end users, the DNA diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. Hospitals have increasingly outsourced diagnostic tests to diagnostic laboratories to reduce the costs and technical issues in managing laboratories. Many small and medium-sized private hospitals and clinics have adopted this trend, thereby driving growth in this segment.
“The Asia Pacific region is projected to witness highest growth rate in the DNA diagnostics market during the forecast period”
The global DNA diagnostics market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR in the DNA diagnostics market during the forecast period. Due to factors like government initiatives to raise awareness about early disease detection and routine health checkups, steadily rising healthcare costs, an increase in hospitals and clinical diagnostics laboratories in China and India, and strengthening research bases for diagnostic procedures across China, Japan, and India, the Asia Pacific market is anticipated to grow at the highest rate during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America – 35%, Europe – 26%, Asia Pacific – 24%, Latin America – 12%, Middle East & Africa – 2%, and the GCC Countries – 1%
Illumina, Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMйrieux (France), Hologic, Inc. (US), QIAGEN (Germany), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Revvity, Inc. (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), Grifols S.A. (Spain), Quidelortho Corporation (US), Amoy Diagnostics Co., Ltd (China), Molbio Diagnostics Pvt. Ltd. (India), Biocartis (Belgium), Exact Sciences Corporation (US), TBG Diagnostics Ltd (Australia), Genetic Signatures (Australia), and Vela Diagnostics (Singapore).
Research Coverage:
In this report, the DNA diagnostics market has been categorized based on technology (polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies), specimen (blood, serum, and plasma, urine, and other specimens), offering (reagents & kits, instruments, and services & software), end user (diagnostic laboratories, hospitals & clinics, application (infectious disease diagnostic, oncology testing, prenatal, pre-implantation, myogenic disorder, and other applications), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).
The report's coverage includes comprehensive details about the key factors impacting the growth of the DNA diagnostics market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, services offered, significant strategies, acquisitions, and partnerships, product launches, and other recent developments related to the DNA diagnostics market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging DNA diagnostics startups.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall DNA diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, trends, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers: (Rising incidence of chronic and infectious diseases, Rising focus on R&D and increased funding by healthcare-based companies, Growing demand for early disease diagnosis an dpersonalized medicine in developing countries, and Technological advancements in DNA diagnostics industry), challenges (Changing regulatory landscape for IVD and DNA diagnostics in US and European Union, Operational barriers and shortage of skills across major markets, and Introductio of alternatives technologies for disease detection and diagnosis), opportunities (Growing significance of companion diagnostics in drug development process, Increasing growth opportunities for DNA diagnostic companies in emerging economies, Advancements in bioinformatics and artificial intelligence in DNA diagnostics and Expansion of direct-to-consumer (DTC) genetic tetsing), and restraints (Unfavourable reimbursement scenario for diagnostic companies, High cost of DNA diagnostic instruments, and Ethical and privacy concerns associated with DNA diagnosis) influencing the growth of the in DNA diagnostics market.
- Product Development/Innovation: Detailed insights on research & development activities and new product launches and approvals in the DNA diagnostics market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the DNA diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the DNA diagnostics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Illumina, Inc. (US), Danaher Corporation (US), and F. Hoffmann-La Roche Ltd. (Switzerland) are among others, in the DNA diagnostics market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 DNA DIAGNOSTICS MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 DNA DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 6 DNA DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
2.9 RECESSION IMPACT ON DNA DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 DNA DIAGNOSTICS MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
FIGURE 9 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 10 DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
FIGURE 11 DNA DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 12 DNA DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 13 GEOGRAPHIC SNAPSHOT OF DNA DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 DNA DIAGNOSTICS MARKET OVERVIEW
FIGURE 14 RISING PREVALENCE OF CHRONIC, GENETIC, AND INFECTIOUS DISEASES TO DRIVE MARKET
4.2 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY AND COUNTRY (2023)
FIGURE 15 PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
4.3 DNA DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH RATE IN DNA DIAGNOSTICS MARKET FROM 2024 TO 2029
4.4 DNA DIAGNOSTICS MARKET: REGIONAL MIX (2024–2029)
FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 DNA DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 DNA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of chronic, infectious, and genetic diseases
FIGURE 20 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION)
5.2.1.2 Rising focus on R&D and increased funding by healthcare companies
5.2.1.3 Growing demand for early disease diagnosis and personalized medicine in developing countries
5.2.1.4 Technological advancements in DNA diagnostics industry
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
5.2.2.2 High cost of DNA diagnostic instruments
5.2.2.3 Ethical and privacy concerns associated with DNA diagnosis
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics in drug development process
5.2.3.2 Increasing growth opportunities for DNA diagnostic companies in emerging economies
5.2.3.3 Advancements in bioinformatics and artificial intelligence in DNA diagnostics
5.2.3.4 Expansion of direct-to-consumer (DTC) genetic testing
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape for IVD and DNA diagnostics in US and European Union
5.2.4.2 Operational barriers and shortage of skills across major markets
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
5.3 PRICING ANALYSIS
5.3.1 PRICING ANALYSIS, BY REGION
TABLE 2 AVERAGE SELLING PRICE OF DNA DIAGNOSTIC PRODUCTS, BY REGION, 2021–2023
5.3.2 PRICING ANALYSIS, BY PRODUCT
TABLE 3 PRICING ANALYSIS OF DNA DIAGNOSTIC PRODUCTS, 2021–2023
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS OF DNA DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 22 DNA DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 23 DNA DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
5.6.1 DNA DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 DNA DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 24 DNA DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
TABLE 5 EUROPE: CLASSIFICATION OF DEVICES
5.8.3 ASIA PACIFIC
5.8.3.1 China
5.8.3.2 Japan
TABLE 6 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.3.3 India
5.8.4 LATIN AMERICA
5.8.4.1 Brazil
5.8.4.2 Mexico
5.8.5 MIDDLE EAST
5.8.6 AFRICA
5.8.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Polymerase chain reaction
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Sequencing technology
5.9.2.2 DNA microarrays
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Isothermal nucleic acid amplification technology
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 12 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2023 (USD MILLION)
TABLE 13 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2023 (USD MILLION)
5.11 PATENT ANALYSIS
FIGURE 25 PATENT ANALYSIS FOR DNA DIAGNOSTICS (JANUARY 2013–DECEMBER 2023)
5.11.1 LIST OF MAJOR PATENTS
5.12 KEY CONFERENCES AND EVENTS IN 2024–2025
TABLE 14 DNA DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2024–2025
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SHIFT IN DNA DIAGNOSTICS MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS (%)
5.15.2 BUYING CRITERIA
FIGURE 27 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS
TABLE 16 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS
5.16 INVESTMENT & FUNDING SCENARIO
FIGURE 28 DNA DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO
6 DNA DIAGNOSTICS MARKET, BY OFFERING
6.1 INTRODUCTION
TABLE 17 DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 18 PRICE OF DNA DIAGNOSTIC PRODUCTS (2023)
6.2 REAGENTS & KITS
6.2.1 RECURRENT PURCHASE FOR DIAGNOSTICS TO PROPEL MARKET
TABLE 19 DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 20 NORTH AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 EUROPE: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 ASIA PACIFIC: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 23 LATIN AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET
TABLE 25 DNA DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 NORTH AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 EUROPE: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 ASIA PACIFIC: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 29 LATIN AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH
TABLE 30 DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 31 NORTH AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 EUROPE: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 ASIA PACIFIC: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 34 LATIN AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 35 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
7.2 POLYMERASE CHAIN REACTION
7.2.1 GROWING USE OF PCR IN GENOMICS TO DRIVE MARKET
TABLE 36 DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)
TABLE 37 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 EUROPE: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 39 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 MICROARRAY
7.3.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
TABLE 41 DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION, 2022–2029 (USD MILLION)
TABLE 42 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 EUROPE: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 45 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 IN SITU HYBRIDIZATION
7.4.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
TABLE 46 DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 EUROPE: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
7.5 SEQUENCING
7.5.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
TABLE 51 DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
TABLE 52 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53 EUROPE: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
7.6 MASS SPECTROSCOPY
7.6.1 TECHNOLOGICAL ADVANCEMENTS IN MASS SPECTROMETERS TO DRIVE ADOPTION
TABLE 56 DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
TABLE 57 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 EUROPE: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
7.7 OTHER TECHNOLOGIES
TABLE 61 DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 62 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 64 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
8 DNA DIAGNOSTICS MARKET, BY SPECIMEN
8.1 INTRODUCTION
TABLE 66 DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 67 DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022–2029 (USD MILLION)
TABLE 68 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 EUROPE: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 URINE
8.3.1 NONINVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
TABLE 72 DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION, 2022–2029 (USD MILLION)
TABLE 73 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 EUROPE: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
8.4 OTHER SPECIMENS
TABLE 77 DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2022–2029 (USD MILLION)
TABLE 78 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 79 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 80 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
9 DNA DIAGNOSTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 82 DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 INFECTIOUS DISEASE DIAGNOSTICS
TABLE 83 DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 84 DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 87 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.1 HEPATITIS
9.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive growth
TABLE 89 DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 EUROPE: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 93 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.2 HIV
9.2.2.1 Increasing prevalence of HIV to propel market
TABLE 94 DNA DIAGNOSTICS MARKET FOR HIV, BY REGION, 2022–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 EUROPE: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.3 CT/NG
9.2.3.1 Increasing prevalence of CT/NG infections to support market growth
TABLE 99 DNA DIAGNOSTICS MARKET FOR CT/NG, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.4 HPV
9.2.4.1 Technological advancements for preventing HPV infections to drive market
TABLE 104 DNA DIAGNOSTICS MARKET FOR HPV, BY REGION, 2022–2029 (USD MILLION)
TABLE 105 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 EUROPE: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.5 OTHER INFECTIOUS DISEASES
TABLE 109 DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 110 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 111 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
9.3 ONCOLOGY TESTING
9.3.1 GROWING SIGNIFICANCE OF PRECISION MEDICINE AND PERSONALIZED APPROACHES IN CANCER CARE TO DRIVE MARKET
TABLE 114 DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2022–2029 (USD MILLION)
TABLE 115 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 EUROPE: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 117 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
9.4 MYOGENIC DISORDERS
9.4.1 DIAGNOSIS OF VARIOUS MYOGENIC DISORDERS THROUGH DNA TESTING TO PROPEL MARKET
TABLE 119 DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 120 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 121 EUROPE: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 122 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
9.5 PRENATAL
9.5.1 INCREASING DEMAND FOR EARLY DETECTION OF GENETIC DISORDERS TO BOOST MARKET GROWTH
TABLE 124 DNA DIAGNOSTICS MARKET FOR PRENATAL, BY REGION, 2022–2029 (USD MILLION)
TABLE 125 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 EUROPE: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION)
9.6 PREIMPLANTATION
9.6.1 GROWING NUMBER OF FERTILITY CLINICS AND IVF CENTERS TO PROPEL MARKET
TABLE 129 NUMBER OF PREIMPLANTATION TESTS PERFORMED, BY COUNTRY, 2022–2029
TABLE 130 DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY REGION, 2022–2029 (USD MILLION)
TABLE 131 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 EUROPE: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION)
9.7 OTHER APPLICATIONS
TABLE 135 DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 136 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
10 DNA DIAGNOSTICS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 140 DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASED OUTSOURCING OF DIAGNOSTIC TESTS BY HOSPITALS TO DRIVE MARKET
TABLE 141 DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 142 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 EUROPE: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 145 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
10.3 HOSPITALS & CLINICS
10.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST GROWTH
TABLE 146 DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 147 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 EUROPE: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 150 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
10.4 OTHER END USERS
TABLE 151 DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 155 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
11 DNA DIAGNOSTICS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 156 DNA DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: DNA DIAGNOSTICS MARKET SNAPSHOT
TABLE 157 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 159 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 160 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 161 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 162 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 163 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
TABLE 164 US: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 165 US: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 166 US: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 167 US: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 168 US: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 169 US: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 US: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising prevalence of cancer and availability of healthcare funding to support market growth
TABLE 171 CANADA: CANCER DEATHS, BY TYPE, 2024 (%)
TABLE 172 CANADA: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 173 CANADA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 174 CANADA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 175 CANADA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 176 CANADA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 177 CANADA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 CANADA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3 EUROPE
TABLE 179 EUROPE: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 180 EUROPE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 181 EUROPE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 182 EUROPE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 183 EUROPE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 184 EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 185 EUROPE: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Favorable government policies and rising per capita disposable income to propel market
TABLE 186 GERMANY: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 187 GERMANY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 188 GERMANY: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 189 GERMANY: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 190 GERMANY: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 191 GERMANY: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 192 GERMANY: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Growing number of accredited diagnostic laboratories to drive market
TABLE 193 UK: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 194 UK: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 195 UK: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 196 UK: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 197 UK: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 198 UK: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
TABLE 199 FRANCE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 200 FRANCE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 201 FRANCE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 202 FRANCE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 203 FRANCE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 204 FRANCE: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Adoption of advanced diagnostic technologies to support market growth
TABLE 205 ITALY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 206 ITALY: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 207 ITALY: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 208 ITALY: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 209 ITALY: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 ITALY: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
TABLE 211 SPAIN: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 212 SPAIN: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 213 SPAIN: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 214 SPAIN: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 215 SPAIN: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 216 SPAIN: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 217 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 218 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 219 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 220 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 221 REST OF EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 222 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 DNA DIAGNOSTICS MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 DNA DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 6 DNA DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
2.9 RECESSION IMPACT ON DNA DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 DNA DIAGNOSTICS MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
FIGURE 9 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 10 DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
FIGURE 11 DNA DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 12 DNA DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 13 GEOGRAPHIC SNAPSHOT OF DNA DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 DNA DIAGNOSTICS MARKET OVERVIEW
FIGURE 14 RISING PREVALENCE OF CHRONIC, GENETIC, AND INFECTIOUS DISEASES TO DRIVE MARKET
4.2 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY AND COUNTRY (2023)
FIGURE 15 PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
4.3 DNA DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH RATE IN DNA DIAGNOSTICS MARKET FROM 2024 TO 2029
4.4 DNA DIAGNOSTICS MARKET: REGIONAL MIX (2024–2029)
FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 DNA DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 DNA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of chronic, infectious, and genetic diseases
FIGURE 20 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION)
5.2.1.2 Rising focus on R&D and increased funding by healthcare companies
5.2.1.3 Growing demand for early disease diagnosis and personalized medicine in developing countries
5.2.1.4 Technological advancements in DNA diagnostics industry
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
5.2.2.2 High cost of DNA diagnostic instruments
5.2.2.3 Ethical and privacy concerns associated with DNA diagnosis
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics in drug development process
5.2.3.2 Increasing growth opportunities for DNA diagnostic companies in emerging economies
5.2.3.3 Advancements in bioinformatics and artificial intelligence in DNA diagnostics
5.2.3.4 Expansion of direct-to-consumer (DTC) genetic testing
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape for IVD and DNA diagnostics in US and European Union
5.2.4.2 Operational barriers and shortage of skills across major markets
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
5.3 PRICING ANALYSIS
5.3.1 PRICING ANALYSIS, BY REGION
TABLE 2 AVERAGE SELLING PRICE OF DNA DIAGNOSTIC PRODUCTS, BY REGION, 2021–2023
5.3.2 PRICING ANALYSIS, BY PRODUCT
TABLE 3 PRICING ANALYSIS OF DNA DIAGNOSTIC PRODUCTS, 2021–2023
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS OF DNA DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 22 DNA DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 23 DNA DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
5.6.1 DNA DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 DNA DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 24 DNA DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
TABLE 5 EUROPE: CLASSIFICATION OF DEVICES
5.8.3 ASIA PACIFIC
5.8.3.1 China
5.8.3.2 Japan
TABLE 6 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.3.3 India
5.8.4 LATIN AMERICA
5.8.4.1 Brazil
5.8.4.2 Mexico
5.8.5 MIDDLE EAST
5.8.6 AFRICA
5.8.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Polymerase chain reaction
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Sequencing technology
5.9.2.2 DNA microarrays
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Isothermal nucleic acid amplification technology
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 12 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2023 (USD MILLION)
TABLE 13 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2023 (USD MILLION)
5.11 PATENT ANALYSIS
FIGURE 25 PATENT ANALYSIS FOR DNA DIAGNOSTICS (JANUARY 2013–DECEMBER 2023)
5.11.1 LIST OF MAJOR PATENTS
5.12 KEY CONFERENCES AND EVENTS IN 2024–2025
TABLE 14 DNA DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2024–2025
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SHIFT IN DNA DIAGNOSTICS MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS (%)
5.15.2 BUYING CRITERIA
FIGURE 27 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS
TABLE 16 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS
5.16 INVESTMENT & FUNDING SCENARIO
FIGURE 28 DNA DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO
6 DNA DIAGNOSTICS MARKET, BY OFFERING
6.1 INTRODUCTION
TABLE 17 DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 18 PRICE OF DNA DIAGNOSTIC PRODUCTS (2023)
6.2 REAGENTS & KITS
6.2.1 RECURRENT PURCHASE FOR DIAGNOSTICS TO PROPEL MARKET
TABLE 19 DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 20 NORTH AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 EUROPE: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 ASIA PACIFIC: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 23 LATIN AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET
TABLE 25 DNA DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 NORTH AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 EUROPE: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 ASIA PACIFIC: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 29 LATIN AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH
TABLE 30 DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 31 NORTH AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 EUROPE: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 ASIA PACIFIC: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 34 LATIN AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 35 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
7.2 POLYMERASE CHAIN REACTION
7.2.1 GROWING USE OF PCR IN GENOMICS TO DRIVE MARKET
TABLE 36 DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)
TABLE 37 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 EUROPE: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 39 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 MICROARRAY
7.3.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
TABLE 41 DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION, 2022–2029 (USD MILLION)
TABLE 42 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 EUROPE: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 45 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 IN SITU HYBRIDIZATION
7.4.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
TABLE 46 DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 EUROPE: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
7.5 SEQUENCING
7.5.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
TABLE 51 DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
TABLE 52 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53 EUROPE: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
7.6 MASS SPECTROSCOPY
7.6.1 TECHNOLOGICAL ADVANCEMENTS IN MASS SPECTROMETERS TO DRIVE ADOPTION
TABLE 56 DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
TABLE 57 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 EUROPE: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
7.7 OTHER TECHNOLOGIES
TABLE 61 DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 62 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 64 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
8 DNA DIAGNOSTICS MARKET, BY SPECIMEN
8.1 INTRODUCTION
TABLE 66 DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 67 DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022–2029 (USD MILLION)
TABLE 68 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 EUROPE: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 URINE
8.3.1 NONINVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
TABLE 72 DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION, 2022–2029 (USD MILLION)
TABLE 73 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 EUROPE: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
8.4 OTHER SPECIMENS
TABLE 77 DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2022–2029 (USD MILLION)
TABLE 78 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 79 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 80 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
9 DNA DIAGNOSTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 82 DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 INFECTIOUS DISEASE DIAGNOSTICS
TABLE 83 DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 84 DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 87 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.1 HEPATITIS
9.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive growth
TABLE 89 DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 EUROPE: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 93 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.2 HIV
9.2.2.1 Increasing prevalence of HIV to propel market
TABLE 94 DNA DIAGNOSTICS MARKET FOR HIV, BY REGION, 2022–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 EUROPE: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.3 CT/NG
9.2.3.1 Increasing prevalence of CT/NG infections to support market growth
TABLE 99 DNA DIAGNOSTICS MARKET FOR CT/NG, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.4 HPV
9.2.4.1 Technological advancements for preventing HPV infections to drive market
TABLE 104 DNA DIAGNOSTICS MARKET FOR HPV, BY REGION, 2022–2029 (USD MILLION)
TABLE 105 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 EUROPE: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION)
9.2.5 OTHER INFECTIOUS DISEASES
TABLE 109 DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 110 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 111 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
9.3 ONCOLOGY TESTING
9.3.1 GROWING SIGNIFICANCE OF PRECISION MEDICINE AND PERSONALIZED APPROACHES IN CANCER CARE TO DRIVE MARKET
TABLE 114 DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2022–2029 (USD MILLION)
TABLE 115 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 EUROPE: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 117 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
9.4 MYOGENIC DISORDERS
9.4.1 DIAGNOSIS OF VARIOUS MYOGENIC DISORDERS THROUGH DNA TESTING TO PROPEL MARKET
TABLE 119 DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 120 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 121 EUROPE: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 122 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
9.5 PRENATAL
9.5.1 INCREASING DEMAND FOR EARLY DETECTION OF GENETIC DISORDERS TO BOOST MARKET GROWTH
TABLE 124 DNA DIAGNOSTICS MARKET FOR PRENATAL, BY REGION, 2022–2029 (USD MILLION)
TABLE 125 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 EUROPE: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION)
9.6 PREIMPLANTATION
9.6.1 GROWING NUMBER OF FERTILITY CLINICS AND IVF CENTERS TO PROPEL MARKET
TABLE 129 NUMBER OF PREIMPLANTATION TESTS PERFORMED, BY COUNTRY, 2022–2029
TABLE 130 DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY REGION, 2022–2029 (USD MILLION)
TABLE 131 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 EUROPE: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION)
9.7 OTHER APPLICATIONS
TABLE 135 DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 136 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
10 DNA DIAGNOSTICS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 140 DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASED OUTSOURCING OF DIAGNOSTIC TESTS BY HOSPITALS TO DRIVE MARKET
TABLE 141 DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 142 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 EUROPE: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 145 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
10.3 HOSPITALS & CLINICS
10.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST GROWTH
TABLE 146 DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 147 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 EUROPE: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 150 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
10.4 OTHER END USERS
TABLE 151 DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 155 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
11 DNA DIAGNOSTICS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 156 DNA DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: DNA DIAGNOSTICS MARKET SNAPSHOT
TABLE 157 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 159 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 160 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 161 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 162 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 163 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
TABLE 164 US: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 165 US: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 166 US: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 167 US: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 168 US: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 169 US: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 US: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising prevalence of cancer and availability of healthcare funding to support market growth
TABLE 171 CANADA: CANCER DEATHS, BY TYPE, 2024 (%)
TABLE 172 CANADA: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 173 CANADA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 174 CANADA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 175 CANADA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 176 CANADA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 177 CANADA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 CANADA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3 EUROPE
TABLE 179 EUROPE: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 180 EUROPE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 181 EUROPE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 182 EUROPE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 183 EUROPE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 184 EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 185 EUROPE: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Favorable government policies and rising per capita disposable income to propel market
TABLE 186 GERMANY: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 187 GERMANY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 188 GERMANY: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 189 GERMANY: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 190 GERMANY: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 191 GERMANY: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 192 GERMANY: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Growing number of accredited diagnostic laboratories to drive market
TABLE 193 UK: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 194 UK: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 195 UK: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 196 UK: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 197 UK: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 198 UK: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
TABLE 199 FRANCE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 200 FRANCE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 201 FRANCE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 202 FRANCE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 203 FRANCE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 204 FRANCE: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Adoption of advanced diagnostic technologies to support market growth
TABLE 205 ITALY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 206 ITALY: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 207 ITALY: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 208 ITALY: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 209 ITALY: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 ITALY: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
TABLE 211 SPAIN: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 212 SPAIN: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 213 SPAIN: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 214 SPAIN: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 215 SPAIN: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 216 SPAIN: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 217 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 218 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 219 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
TABLE 220 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 221 REST OF EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 222 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
